A detailed history of Hillsdale Investment Management Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 260 shares of CSTL stock, worth $7,157. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260
Previous 300 13.33%
Holding current value
$7,157
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$17.4 - $31.47 $696 - $1,258
-40 Reduced 13.33%
260 $7,000
Q1 2024

May 10, 2024

BUY
$18.06 - $25.3 $5,418 - $7,590
300 New
300 $6,000
Q2 2020

Aug 11, 2020

SELL
$27.28 - $43.01 $256,432 - $404,294
-9,400 Closed
0 $0
Q1 2020

May 12, 2020

BUY
$23.08 - $35.53 $216,951 - $333,982
9,400 New
9,400 $281,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $724M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Hillsdale Investment Management Inc. Portfolio

Follow Hillsdale Investment Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hillsdale Investment Management Inc. with notifications on news.